These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 32749651)

  • 1. Therapy of Parkinson's Disease Subtypes.
    Marras C; Chaudhuri KR; Titova N; Mestre TA
    Neurotherapeutics; 2020 Oct; 17(4):1366-1377. PubMed ID: 32749651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonmotor features of Parkinson's disease subtypes.
    Marras C; Chaudhuri KR
    Mov Disord; 2016 Aug; 31(8):1095-102. PubMed ID: 26861861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional Study.
    Simuni T; Brumm MC; Uribe L; Caspell-Garcia C; Coffey CS; Siderowf A; Alcalay RN; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Nudelman K; Tosun-Turgut D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten S; Bressman S; Marek K;
    Mov Disord; 2020 May; 35(5):833-844. PubMed ID: 32073681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Precision medicine in Parkinson's disease patients with LRRK2 and GBA risk variants - Let's get even more personal.
    von Linstow CU; Gan-Or Z; Brundin P
    Transl Neurodegener; 2020 Oct; 9(1):39. PubMed ID: 33066808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New therapeutic approaches to Parkinson's disease targeting GBA, LRRK2 and Parkin.
    Senkevich K; Rudakou U; Gan-Or Z
    Neuropharmacology; 2022 Jan; 202():108822. PubMed ID: 34626666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Motor subtypes and clinical characteristics in sporadic and genetic Parkinson's disease groups: analysis of the PPMI cohort.
    Jeong EH; Lee JY; Han SK; Song YS
    Front Neurol; 2023; 14():1276251. PubMed ID: 37954645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utility of plasma Neurofilament light as a diagnostic and prognostic biomarker of the postural instability gait disorder motor subtype in early Parkinson's disease.
    Ng ASL; Tan YJ; Yong ACW; Saffari SE; Lu Z; Ng EY; Ng SYE; Chia NSY; Choi X; Heng D; Neo S; Xu Z; Keong NCH; Tay KY; Au WL; Tan LCS; Tan EK
    Mol Neurodegener; 2020 Jun; 15(1):33. PubMed ID: 32503574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study.
    Simuni T; Uribe L; Cho HR; Caspell-Garcia C; Coffey CS; Siderowf A; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Tosun D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten SJ; Bressman S; Marek K;
    Lancet Neurol; 2020 Jan; 19(1):71-80. PubMed ID: 31678032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subtypes of Parkinson's disease: state of the field and future directions.
    Marras C
    Curr Opin Neurol; 2015 Aug; 28(4):382-6. PubMed ID: 26110797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low Levels of LRRK2 Gene Expression are Associated with LRRK2 SNPs and Contribute to Parkinson's Disease Progression.
    Yılmazer S; Candaş E; Genç G; Alaylıoğlu M; Şengül B; Gündüz A; Apaydın H; Kızıltan G; Ertan S; Dursun E; Gezen-Ak D
    Neuromolecular Med; 2021 Jun; 23(2):292-304. PubMed ID: 33015738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Precision medicine in Parkinson's disease: emerging treatments for genetic Parkinson's disease.
    Schneider SA; Alcalay RN
    J Neurol; 2020 Mar; 267(3):860-869. PubMed ID: 31974807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical profiles associated with LRRK2 and GBA mutations in Brazilians with Parkinson's disease.
    da Silva CP; de M Abreu G; Cabello Acero PH; Campos M; Pereira JS; de A Ramos SR; Nascimento CM; Voigt DD; Rosso AL; Araujo Leite MA; Vasconcellos LFR; Nicaretta DH; Della Coletta MV; da Silva DJ; Gonçalves AP; Dos Santos JM; Calassara V; Valença DCT; de M Martins CJ; Santos-Rebouças CB; Pimentel MMG
    J Neurol Sci; 2017 Oct; 381():160-164. PubMed ID: 28991672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carriers of both GBA and LRRK2 mutations, compared to carriers of either, in Parkinson's disease: Risk estimates and genotype-phenotype correlations.
    Yahalom G; Greenbaum L; Israeli-Korn S; Fay-Karmon T; Livneh V; Ruskey JA; Roncière L; Alam A; Gan-Or Z; Hassin-Baer S
    Parkinsonism Relat Disord; 2019 May; 62():179-184. PubMed ID: 30573413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study.
    Healy DG; Falchi M; O'Sullivan SS; Bonifati V; Durr A; Bressman S; Brice A; Aasly J; Zabetian CP; Goldwurm S; Ferreira JJ; Tolosa E; Kay DM; Klein C; Williams DR; Marras C; Lang AE; Wszolek ZK; Berciano J; Schapira AH; Lynch T; Bhatia KP; Gasser T; Lees AJ; Wood NW;
    Lancet Neurol; 2008 Jul; 7(7):583-90. PubMed ID: 18539534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of clinical features among Parkinson's disease subtypes: A large retrospective study in a single center.
    Konno T; Deutschländer A; Heckman MG; Ossi M; Vargas ER; Strongosky AJ; van Gerpen JA; Uitti RJ; Ross OA; Wszolek ZK
    J Neurol Sci; 2018 Mar; 386():39-45. PubMed ID: 29406964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Motor and nonmotor heterogeneity of LRRK2-related and idiopathic Parkinson's disease.
    Marras C; Alcalay RN; Caspell-Garcia C; Coffey C; Chan P; Duda JE; Facheris MF; Fernández-Santiago R; Ruíz-Martínez J; Mestre T; Saunders-Pullman R; Pont-Sunyer C; Tolosa E; Waro B;
    Mov Disord; 2016 Aug; 31(8):1192-202. PubMed ID: 27091104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Parkinson's Disease-Associated Mutation LRRK2-G2019S Impairs Synaptic Plasticity in Mouse Hippocampus.
    Sweet ES; Saunier-Rebori B; Yue Z; Blitzer RD
    J Neurosci; 2015 Aug; 35(32):11190-5. PubMed ID: 26269629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonmotor Subtyping in Parkinson's Disease.
    Sauerbier A; Rosa-Grilo M; Qamar MA; Chaudhuri KR
    Int Rev Neurobiol; 2017; 133():447-478. PubMed ID: 28802928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Possible Modifying Effect of the G2019S Mutation in the LRRK2 Gene on GBA Parkinson's Disease.
    Omer N; Giladi N; Gurevich T; Bar-Shira A; Gana-Weisz M; Goldstein O; Kestenbaum M; Cedarbaum JM; Orr-Urtreger A; Mirelman A; Thaler A
    Mov Disord; 2020 Jul; 35(7):1249-1253. PubMed ID: 32353202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical profiles of Parkinson's disease associated with common leucine-rich repeat kinase 2 and glucocerebrosidase genetic variants in Chinese individuals.
    Wang C; Cai Y; Gu Z; Ma J; Zheng Z; Tang BS; Xu Y; Zhou Y; Feng T; Wang T; Chen SD; Chan P;
    Neurobiol Aging; 2014 Mar; 35(3):725.e1-6. PubMed ID: 24095219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.